The article mentions that Castle Biosciences has received 1 bullish and 6 somewhat bullish ratings from analysts in the last quarter. This indicates a positive sentiment towards the stock. However, the average 12-month price target has decreased by 13.87% from the previous average, which may suggest a more cautious outlook. The impact on the stock price is likely to be positive in the short term due to the overall positive sentiment from analysts.